Business
Strategic and Operational Update
Strategic and Operational Update.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 6555X IXICO plc 28 November 2017 \n\n28 November 2017\n \nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nStrategic and Operational Update\n \nBuilding scale and momentum with commercially-led growth\nNotice of Final Results\n \nIXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today outlines its commercially led growth strategy as defined by Giulio Cerroni, Chief Executive Officer.\n \nGiulio Cerroni, said: \"Following my appointment in February 2017 I have completed an operational review of the Company. Below, I have set out my plan to drive IXICO forward as a high growth and scalable technology business focused on specialised areas of the digital healthcare market. I have also provided an update on our recent progress as we start to deliver on our objective to Build on our core strengths and Grow our capabilities to Scale our Company.\"\n \n\"I believe that IXICO is well positioned to benefit from a number of market tailwinds as the biopharmaceutical industry looks to leverage digital technologies in both drug development and the way that medical care is delivered. Therefore, in my first months my priority has been to ensure that as an organisation we have a \"razor-sharp\" focus on our customer's needs, supporting their business goals, better than our competitors.\n \n\"My review confirmed that our focus on neurological disorders in a growing market will support our double digit organic growth objectives. I also considered how to best leverage the Company's existing technology and commercial assets. The outcome was a commercially-led growth plan to deliver top-line growth through our existing customer relationships and targeting new biopharmaceutical customers to further progress our market penetration.\n \nAs part of our strategy we will look to supplement this organic growth with the acquisition of complementary specialist technologies, while keeping focused on our over-arching goal of an accelerated path to profitability.\"\n \nStrategy\n \nSector focus\nWe will build on IXICO's trusted position in providing neuro-imaging technology enabled specialist services to the biopharmaceutical industry. We have identified three key value segments where IXICO's technology platform and capabilities are mission critical and where our di...